Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe community-acquired pneumonia.

Francisco Alvarez-Lerma1, Antoni Torres

  • 1Service de Medicina Intensiva, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

Current Opinion in Critical Care
|September 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?

American journal of respiratory and critical care medicine·2020
Same author

Biomarkers in the ICU: less is more? No.

Intensive care medicine·2020
Same author

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine·2020
Same author

Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.

Annals of the American Thoracic Society·2020
Same author

Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience.

Respiratory medicine·2020

Severe community-acquired pneumonia management is guided by validated severity scores, not inflammatory markers. Adequate empiric antibiotic treatment improves outcomes, but early administration or knowing the cause shows no definitive benefit.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pulmonology

Background:

  • Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality.
  • Severe CAP necessitates inpatient care, often including intensive care unit (ICU) admission, and is associated with a poorer prognosis.

Purpose of the Study:

  • To review and comment on original research published since April 1, 2003, concerning severe community-acquired pneumonia.
  • To assess advancements in illness severity assessment, etiology, diagnostics, and treatment options for severe CAP.

Main Methods:

  • Descriptive review of original articles published from April 1, 2003, onwards.
  • Analysis of literature focusing on inflammatory markers, severity scores, treatment strategies, and antimicrobial efficacy.

Related Experiment Videos

Main Results:

  • Validation of severity scores provides reliable tools for classifying patients and optimizing hospital/ICU admission.
  • Adequate empiric antibiotic treatment significantly impacts clinical outcomes.
  • The efficacy of new antimicrobials and the impact of early antibiotic administration or etiological diagnosis remain areas for further investigation.

Conclusions:

  • Severity scores are conclusive for risk stratification in severe CAP.
  • Empiric antibiotic therapy is crucial for favorable outcomes, with no clear benefit of early administration or etiological knowledge.
  • The role of inflammatory markers in predicting outcomes for severe CAP requires further clarification.